Welcome to our dedicated page for Ashland SEC filings (Ticker: ASH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ashland Inc. (NYSE: ASH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a global additives and specialty ingredients company serving architectural coatings, construction, energy, food and beverage, personal care and pharmaceutical markets, Ashland uses these filings to report on its financial condition, governance and strategic priorities.
Investors can review current reports on Form 8-K, where Ashland discloses material events such as quarterly and annual results, outlook updates, leadership changes, board resignations or appointments, and certain compensation arrangements. For example, recent 8-K filings have addressed preliminary earnings results, production network developments and executive appointments.
The annual proxy statement on Schedule 14A (DEF 14A) offers detailed information on Ashland’s board structure, executive compensation, stock repurchase programs, dividend practices and ESG and sustainability focus. The 2026 proxy statement highlights themes such as Execute, Globalize, Innovate and Invest, portfolio optimization, manufacturing network optimization and progress toward Science Based Targets initiative emissions goals.
Through this page, users can also access Ashland’s periodic reports, including annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain segment discussions for Life Sciences, Personal Care, Specialty Additives and Intermediates, along with risk factors and management’s analysis.
Stock Titan enhances these documents with AI-powered summaries that explain key points in plain language, highlight important changes from prior periods and surface items such as segment trends, capital allocation decisions and governance updates. Real-time updates from EDGAR help ensure that new Ashland filings, including Forms 4 reporting insider transactions when available, are quickly reflected so users can analyze ASH regulatory information efficiently.
Ashland Inc. is asking stockholders to review its 2026 proxy and vote at a virtual annual meeting on January 20, 2026. Stockholders will elect eight directors, ratify Ernst & Young LLP as auditor for fiscal 2026, and cast a non-binding advisory vote on executive compensation.
The company, a global additives and specialty ingredients supplier, reports fiscal 2025 sales of $1.824 billion, down after strategic portfolio optimization and the sale of the Avoca business. Fiscal 2025 includes an operating loss of $775 million, driven largely by a $706 million goodwill impairment and a $175 million loss on the Avoca sale. Non-GAAP adjusted EBITDA was $401 million with a 22.0% margin, and adjusted EPS (excluding intangible amortization) was $3.38.
The Board highlights $30 million of restructuring savings, a $60 million manufacturing optimization program, and ongoing globalization and innovation investments. Governance practices include a majority-independent Board, a combined Chair/CEO role balanced by a Lead Independent Director, four fully independent committees, strong attendance, stock ownership guidelines, a clawback policy, and anti-hedging rules. Executive and director pay is positioned as pay-for-performance, with significant equity-based and incentive-linked components tied to metrics such as adjusted EBITDA, innovation revenue, RONA, adjusted EPS and relative total shareholder return.
Standard Investments LLC and affiliates have filed a Schedule 13D on Ashland Inc. after building a sizable position. The group reports beneficial ownership of 2,625,000 shares of Ashland common stock, representing 5.7% of the outstanding shares, based on 45,718,113 shares outstanding as of October 31, 2025. The shares were acquired by Standard Latitude Master Fund for a total purchase price of $133,023,241, funded with working capital through open-market purchases.
In addition, Standard Latitude Master has cash-settled total return swaps referencing 1,900,000 Ashland shares, equal to 4.2% of the outstanding stock, giving the group combined economic exposure to approximately 9.9% of Ashland. The investors state they view Ashland as an attractive opportunity and may engage with management, the board and other stakeholders on topics such as strategy, capital allocation, governance and potential strategic alternatives, and may increase or reduce their position over time.
Ashland Inc. (ASH) reported an equity compensation grant to a senior executive. On 11/19/2025, the company granted its SVP and GM, Life Sciences, 6,136 Restricted Stock Units (RSUs), each representing one share of Ashland common stock. These RSUs vest in three equal installments starting one year from the grant date, as long as the executive remains continuously employed.
On the same date, the executive also received 13,807 Stock Appreciation Rights (SARs) with an exercise price of $50.58 per share. These SARs become exercisable ratably over three years beginning on the first anniversary of the grant and expire on 11/19/2035. The filing reflects ongoing use of Ashland’s shareholder‑approved incentive compensation plans.
Ashland Inc. (ASH) reported an equity compensation grant to a senior executive. On November 19, 2025, the company awarded 3,965 Restricted Stock Units (RSUs), each representing one share of Ashland common stock, and 8,922 Stock Appreciation Rights (SARs) with an exercise price of $50.58 per share.
The RSUs vest in three equal installments beginning one year from the grant date, as long as the executive remains continuously employed with Ashland. The SARs were granted under the Ashland Inc. 2021 Omnibus Incentive Compensation Plan and become exercisable ratably over three years, starting on the first anniversary of the grant date.
Ashland Inc. (ASH) reported an equity award to its Chair and CEO, Guillermo Novo. On 11/19/2025, he received 43,495 Restricted Stock Units (RSUs), each representing one share of Ashland common stock, granted under the company’s shareholder‑approved incentive plan and exempt under Rule 16b-3.
The RSUs vest in three equal installments beginning one year from the grant date, as long as he remains continuously employed. Novo was also granted 97,864 Stock Appreciation Rights (SARs) with an exercise price of $50.58 per share, expiring on 11/19/2035. These SARs become exercisable ratably over three years starting on the first anniversary of the grant date, and both awards are held directly.
Ashland Inc. (ASH) reported an equity award grant to its senior finance executive. William Whitaker, the company’s SVP, CFO and PFO, received 10,280 restricted stock units (RSUs) on November 19, 2025 under Ashland’s shareholder-approved incentive plan. Each RSU represents one share of Ashland common stock and vests in three equal installments starting one year from the grant date, as long as he remains continuously employed.
Whitaker was also granted 23,131 stock appreciation rights (SARs) on the same date at an exercise price of $50.58 per share, expiring on November 19, 2035. These SARs become exercisable ratably over three years beginning on the first anniversary of the grant date.
Ashland Inc. (ASH) filed a Form 4 reporting new equity awards to its SVP and CTO, Osama M. Musa. On November 19, 2025, he received 6,379 Restricted Stock Units (RSUs), each representing one share of Ashland common stock. These RSUs vest in three equal installments starting one year after the grant date, as long as he remains continuously employed by the company.
He was also granted 14,354 Stock Appreciation Rights (SARs) with an exercise price of $50.58 per share under the Ashland Inc. 2021 Omnibus Incentive Compensation Plan. The SARs become exercisable ratably over three years, beginning on the first anniversary of the grant date, and expire on November 19, 2035. These awards are part of Ashland’s shareholder-approved incentive plans.
Ashland Inc. (ASH) reported an equity award for senior vice president and general manager of Personal Care, James P. Minicucci. On 11/19/2025, he received 5,049 Restricted Stock Units (RSUs), each representing one share of Ashland common stock, granted under the company’s shareholder-approved incentive plan. These RSUs vest in three equal installments starting one year from the grant date, contingent on continued employment.
On the same date, he was also granted 11,361 Stock Appreciation Rights (SARs) with an exercise price of $50.58 per share under the Ashland Inc. 2021 Omnibus Incentive Compensation Plan. The SARs become exercisable ratably over three years beginning on the first anniversary of the grant and expire on 11/19/2035.
Ashland Inc. (ASH) reported an equity compensation grant to senior executive Dago Caceres, who serves as SVP & GM, Specialty Additives. On 11/19/2025, Caceres received 4,250 Restricted Stock Units (RSUs), each representing one share of Ashland common stock. These RSUs vest in three equal installments starting one year from the grant date, as long as he remains continuously employed.
On the same date, he was also granted 9,564 Stock Appreciation Rights (SARs) with an exercise price of $50.58 per share under Ashland’s 2021 Omnibus Incentive Compensation Plan. The SARs become exercisable ratably over three years beginning on the first anniversary of the grant and are tied to Ashland common stock. Both awards were issued under shareholder-approved incentive plans and are reported as directly owned.
Ashland Inc. (ASH) reported an equity award for a senior executive. SVP and Chief HRO Eileen Drury received a grant of 3,954 restricted stock units (RSUs) and 8,897 stock appreciation rights (SARs) on November 19, 2025 under Ashland’s shareholder-approved incentive plans.
Each RSU represents one share of Ashland common stock and vests in three equal installments beginning one year from the grant date, as long as she remains continuously employed by the company. The SARs have an exercise price of $50.58 per share, are issued under the 2021 Omnibus Incentive Compensation Plan, and become exercisable ratably over three years starting on the first anniversary of the grant, with an expiration date of November 19, 2035.